Literature DB >> 17101575

Chronic cyclooxygenase blockade enhances the vasopressin responsiveness in collaterals of portal hypertensive rats.

Hui-Chun Huang1, Sun-Sang Wang, Yi-Chou Chen, Fa-Yauh Lee, Full-Young Chang, Han-Chieh Lin, Ming-Chih Hou, Ching-Chih Chang, Shou-Dong Lee.   

Abstract

OBJECTIVE: Collateral vascular responsiveness to vasoconstrictors may be crucial in the management of acute variceal bleeding. In an in situ perfusion model, arginine vasopressin (AVP) has been shown to cause a direct vasoconstrictive effect on portal-systemic collaterals and this effect is enhanced by preincubation of indomethacin (INDO). The purpose of this study was to investigate the effects of chronic INDO administration on the portal-systemic collateral responsiveness to AVP and the degree of portal-systemic shunting in portal hypertensive rats.
MATERIAL AND METHODS: Rats with partial portal vein ligation randomly received daily subcutaneous injections with INDO (5 mg/kg) or distilled water (control group) 2 days prior to until 7 days after ligation. Systemic and portal hemodynamics was evaluated on the 8th day. Using an in situ collateral perfusion model, AVP (10(-10)-10(-7) M) at a constant flow rate (20 ml/min) was applied. In another series, Krebs solution with different flow rates (5-30 ml/min) was used to obtain flow-pressure curves: the slopes represent collateral vascular resistances--the higher resistances indicate fewer collaterals.
RESULTS: Mean arterial pressure and portal pressure were not significantly different between the INDO-treated group and the control group (p>0.05). In the first series of experiments, INDO treatment increased the collateral perfusion pressure to AVP at 10(-8) M, 3x10(-8) M, and 10(-7) M (p<0.05). In the second series, INDO did not change collateral vascular resistance, which suggests that the degree of shunting was not altered.
CONCLUSIONS: Chronic INDO treatment improves the collateral vascular responsiveness to AVP without ameliorating portal-systemic shunting in portal hypertensive rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101575     DOI: 10.1080/00365520600735696

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  2 in total

1.  Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension.

Authors:  Francisco X Eizayaga; Omar Aguejouf; Vanessa Desplat; Philippe Belon; Christian Doutremepuich
Journal:  World J Gastroenterol       Date:  2007-10-14       Impact factor: 5.742

2.  Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.

Authors:  Ching-Chih Chang; Wen-Shin Lee; Hsian-Guey Hsieh; Chiao-Lin Chuang; Hui-Chun Huang; Fa-Yauh Lee; Shou-Dong Lee
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.